An investigation on behalf of investors of Global Blood Therapeutics, Inc. (NASDAQ: GBT) shares over potential securities laws violations by Global Blood Therapeutics and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Global Blood Therapeutics, Inc. (NASDAQ: GBT) concerning whether a series of statements by Global Blood Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Francisco, CA based Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. OnSeptember 13, 2018, Stat published an article describing important risks that investors might be glossing over regarding Global Bloods FDA approval prospects for its new drug to treat sickle cell disease, voxelotor. The article cited the results of a recent Phase 3 clinical trial and stated Global Blood lacks data demonstrating voxelotor reduces the frequency of crises, which is traditionally a necessary criterion for FDA approval of a sickle cell disease treatment. The article further stated that, [i]n the Phase 3 study, voxelotor did not improve the quality of life of sickle cell patients.

Shares of Global Blood Therapeutics, Inc. (NASDAQ: GBT) declined from $65.20 per share in February 2018 to as low as $40.40 per share on September 19, 2018.